Jubilant Pharmova Ltd on Friday said the US health regulator has classified the contract manufacturing (CMO) facility of its step-down subsidiary, Jubilant HollisterStier LLC, in Spokane, Washington, as ‘Voluntary Action Indicated’ (VAI).
The US Food and Drug Administration (US FDA) concluded its review of the Establishment Inspection Report (EIR) for the inspection conducted at the Spokane facility from June 8, 2026, to June 17, 2026, the company said in a regulatory filing.
A VAI classification indicates that while objectionable conditions or practices were found during the inspection, the agency does not intend to recommend any administrative or regulatory action as the company is expected to voluntarily resolve them.
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a unit of Singapore-based Jubilant Pharma Limited—a wholly-owned subsidiary of Jubilant Pharmova Ltd.